Imprimis Pharma (IMMY) Misses Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Imprimis Pharmaceuticals Announces First Quarter 2015 Financial Results and Provides Business Update
May 13, 2015 4:05 PM EDTSAN DIEGO, May 13, 2015 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced its financial results for the first quarter 2015 ended March 31, 2015. Management will discuss the financial results and recent business developments on a conference call this afternoon.
Key First Quarter 2015 Accomplishments and Recent Developments
Revenue of approximately $1.6 million during the first quarter of 2015, compared to $2,000 during the first quarter of 2014; Adjusted EBITDA... More